Last reviewed · How we verify

Brimonidine Tartrate 0.15% Oph Soln

Uptown Eye Specialists · Phase 1 active Small molecule Quality 0/100

Brimonidine Tartrate 0.15% Oph Soln is a Small molecule drug developed by Uptown Eye Specialists. It is currently in Phase 1 development. Also known as: Alphagan-P.

At a glance

Generic nameBrimonidine Tartrate 0.15% Oph Soln
Also known asAlphagan-P
SponsorUptown Eye Specialists
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Brimonidine Tartrate 0.15% Oph Soln

What is Brimonidine Tartrate 0.15% Oph Soln?

Brimonidine Tartrate 0.15% Oph Soln is a Small molecule drug developed by Uptown Eye Specialists.

Who makes Brimonidine Tartrate 0.15% Oph Soln?

Brimonidine Tartrate 0.15% Oph Soln is developed by Uptown Eye Specialists (see full Uptown Eye Specialists pipeline at /company/uptown-eye-specialists).

Is Brimonidine Tartrate 0.15% Oph Soln also known as anything else?

Brimonidine Tartrate 0.15% Oph Soln is also known as Alphagan-P.

What development phase is Brimonidine Tartrate 0.15% Oph Soln in?

Brimonidine Tartrate 0.15% Oph Soln is in Phase 1.

Related